Cancer Research Cancer Health Disparities Conference 2009
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

[Cancer Research 43, 4073-4077, September 1, 1983]
© 1983 American Association for Cancer Research

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kawamura, H.
Right arrow Articles by Yuspa, S. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kawamura, H.
Right arrow Articles by Yuspa, S. H.

Inhibition of 12-O-Tetradecanoylphorbol-13-acetate Induction of Epidermal Transglutaminase Activity by Protease Inhibitors

Hideki Kawamura, James E. Strickland1 and Stuart H. Yuspa

In Vitro Pathogenesis Section, Laboratory of Cellular Carcinogenesis and Tumor Promotion, Division of Cancer Cause and Prevention, National Cancer Institute, Bethesda, Maryland 20205

Pretreatment of primary mouse epidermal cell cultures with chymostation, a protease inhibitor, blocked the increase in transglutaminase (R-glutaminyl-peptide:amine {gamma}-glutamyltransferase, EC 2.3.2.13) activity resulting from treatment with the tumor promoter 12-O-tetradecanoylphorbol-13-acetate (TPA) or with retinoic acid. This inhibitory effect was dependent upon both the concentration of chymostatin used and preincubation time and was eliminated when chymostatin was inactivated by NaBH4 reduction. Five other protease inhibitors, antipain, leupeptin, pepstatin, aprotinin, and soybean trypsin inhibitor, also suppressed TPA induction of transglutaminase activity. However, neither chymostatin, nor antipain, nor leupeptin reduced protein synthesis as measured by incorporation of labeled leucine into acid-precipitable products, while pepstatin, aprotinin, and soybean trypsin inhibitor inhibited protein synthesis markedly. L-1-Tosylamide-2-phenylethylchloromethyl ketone, on the other hand, strongly inhibited protein synthesis but did not inhibit the increase of transglutaminase activity after TPA exposure, and elastatinal inhibited neither TPA action nor protein synthesis. Chymostatin did not block phorbol ester binding to epidermal cells or TPA-mediated reduction of epidermal growth factor binding. These results suggest that the apparent induction of intracellular transglutaminase activity is mediated by a chymostatin-sensitive protease, while both phorbol ester binding and the reduction by TPA of epidermal growth factor binding at the cell membrane were independent.

1 To whom requests for reprints should be addressed, at Room 3A23, Building 37, NIH, Bethesda, Md. 20205.

Received 11/12/82. Accepted 6/ 2/83.







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1983 by the American Association for Cancer Research.